Primary or adjunct chemotherapy with Glo1 inhibitor to counter Glo1-mediated MDR may improve treatment outcomes [20] and high Glo1 expression may be a biomarker of likely tumor susceptibility to Glo1 inhibitor therapy [99]. The gene discussed is GLO1; the disease is neoplasm.